banner
News center
Our goal is to continuously improve our techniques and quality to meet your needs.

WADA publishes revised Technical Documents and Technical Letters | World Anti Doping Agency

Oct 14, 2024

Releases 30 Nov 2021

The World Anti-Doping Agency (WADA) has published revised versions of two Technical documents (TDs) and four Technical Letters (TLs):

REVISED TECHNICAL DOCUMENTS

Under the International Standard for Laboratories (ISL), WADA’s TDs are issued to provide direction to WADA-accredited Laboratories, WADA-approved Laboratories for the Athlete Biological Passport, and other stakeholders, on specific technical or procedural issues. As part of WADA’s mandate to enhance anti-doping activities under the World Anti-Doping Code, TDs undergo periodic revisions to reflect scientific and technological advances in the performance of anti-doping analyses and the reporting of analytical results. They are refined and revised in consultation with WADA stakeholders.

All WADA-accredited Laboratories are required to implement these revised TDs by 1 January 2022.

TD2022LDOC version 1.0:

This TD relates to the preparation of Laboratory Documentation Packages and Laboratory Certificates of Analysis. It replaces the current TD2021LDOC v1.0. The main changes include:

TD2022MRPL version 1.1:

This TD relates to the MRLs for non-threshold substances analyzed by Chromatographic-Mass Spectrometric analytical methods. It replaces the recently approved TD2022MRPL version 1.0. In this new version of the TD, some minor changes and clarifications have been incorporated, which do not affect the substance of the already published TD2022MRPL version 1.0, including among others:

The above TDs are available and indexed on WADA’s website.

REVISED TECHNICAL LETTERS

Under the ISL, WADA’s TLs provide specific direction to WADA-accredited Laboratories, WADA-Approved Laboratories for the Athlete Biological Passport, and other stakeholders on particular issues regarding the analysis, interpretation and reporting of results for specific prohibited substance(s) and/or prohibited method(s) or on the application of specific laboratory procedures.

All WADA-accredited Laboratories are required to implement these revised TLs with immediate effect.

This revised version 4.0 of TL01 includes new guidance on the evaluation and reporting of analytical results for the presence of chlorophenoxyacetic acid (4-CPA), the marker of use of meclofenoxate in urine.

The updates in TL01 follow the recent finding that 4-CPA in urine may originate not only from meclofenoxate or from food containing residues of 4-CPA, but also from chlorphenesin, a non-prohibited substance that is used as a preserving agent in cosmetics and lotions, or from chlorphenesin carbamate, an approved drug for the relief of muscle pain.

In this revised version 3.1 of TL05, a typo in the oxilofrine name in section 2.0: Analysis and Reporting Requirements has been corrected.

The comment in TL10 version 3.1 mentioning that the possible in situ formation of prednisone and prednisolone would be addressed in another TL has been removed from the Introduction section. This update was necessary due to the upcoming withdrawal of the TL19 – Prednisone and Prednisolone.

The updates in this version 2.0 of TL24 include guidance on how a finding for hydrochlorothiazide (HCT) shall be reported when it is detected in conjunction with its degradation product chloraminophenamide (ACB), which is aligned with the recently approved TD2022MRPL.

In addition, TL19 – Prednisone and Prednisolone will no longer be valid from 1 January 2022. The requirements on prednisone and prednisolone analyses are now provided in the TD2022MRPL.

Previously issued TLs are available and indexed on WADA’s website.

Should you have any questions regarding the above TDs or TLs, we invite you to contact WADA’s Science Department at: [email protected].

Releases

Releases

TD2022LDOCTL01TL24TD2022MRPLTL05TL10REVISED TECHNICAL DOCUMENTS1 January 2022TD2022LDOC version 1.0:TD2022MRPL version 1.1:REVISED TECHNICAL LETTERSwith immediate effectTL01: Meclofenoxate version 4.0TL05: Oxilofrine version 3.1TL10: In situ formation of exogenous compounds version 3.1TL19 – Prednisone and PrednisoloneTL24: Diuretics version 2.0TL19 – Prednisone and Prednisolone